These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 11547215)
21. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus. Campbell IW Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991 [TBL] [Abstract][Full Text] [Related]
22. Type II diabetes mellitus. Edelman SV Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190 [TBL] [Abstract][Full Text] [Related]
23. What therapy do our NIDDM patients need? Insulin releasers. Crepaldi G; Del Prato S Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S159-65. PubMed ID: 8529509 [TBL] [Abstract][Full Text] [Related]
24. Recent developments and emerging therapies for type 2 diabetes mellitus. Evans AJ; Krentz AJ Drugs R D; 1999 Aug; 2(2):75-94. PubMed ID: 10820647 [TBL] [Abstract][Full Text] [Related]
25. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus. Kudzma DJ Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410 [TBL] [Abstract][Full Text] [Related]
27. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent. Lam NT; Kieffer TJ Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501 [TBL] [Abstract][Full Text] [Related]
28. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Wolffenbuttel BH; van Haeften TW Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759 [TBL] [Abstract][Full Text] [Related]
29. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Halimi S Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591 [TBL] [Abstract][Full Text] [Related]
30. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Østergaard L; Frandsen CS; Madsbad S Expert Rev Clin Pharmacol; 2016; 9(2):241-65. PubMed ID: 26573176 [TBL] [Abstract][Full Text] [Related]
32. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
34. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy. Brown DL; Brillon D J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211 [TBL] [Abstract][Full Text] [Related]
36. [Repaglinide in combination therapy in type 2 diabetes]. Moses R Diabetes Metab; 1999 Dec; 25 Suppl 7():26-7. PubMed ID: 10746009 [TBL] [Abstract][Full Text] [Related]
37. Type 2 diabetes mellitus: what is the optimal treatment regimen? Bell DS Am J Med; 2004 Mar; 116 Suppl 5A():23S-29S. PubMed ID: 15019860 [TBL] [Abstract][Full Text] [Related]
38. [Nateglinide and mitiglinide]. Odawara M Nihon Rinsho; 2003 Jul; 61(7):1230-7. PubMed ID: 12877090 [TBL] [Abstract][Full Text] [Related]
39. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Vergès B; Bonnard C; Renard E Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831 [TBL] [Abstract][Full Text] [Related]